Change request

Yorkshire Water Selects LTIMindtree as a Strategic Transformation Partner

Retrieved on: 
Thursday, December 22, 2022

LTIMindtree , a global technology consulting and digital solutions company, announced today that it has been selected as a transformation partner by Yorkshire Water, a leading UK utilities company, to modernise operations across its clean water, waste water, and asset management businesses.

Key Points: 
  • LTIMindtree , a global technology consulting and digital solutions company, announced today that it has been selected as a transformation partner by Yorkshire Water, a leading UK utilities company, to modernise operations across its clean water, waste water, and asset management businesses.
  • Yorkshire Water is the ninth largest water utility in the world and provides water and wastewater services to 5.2 million customers across Yorkshire.
  • By automating and simplifying processes, consolidating data, and modernising core systems using intelligent technologies, LTIMindtree will enable Yorkshire Water to boost operational efficiencies, augment capabilities, and enhance user experience.
  • In LTIMindtree, we have a partner who brings a rich portfolio of innovative offerings, and proven track record of helping similar transformation programmes.

DENTALIS Animal Health Develops Products to Improve the Oral Health of Companion Animals

Retrieved on: 
Friday, October 7, 2022

Animal health veterans and human dental experts have combined and formed a start-up company dedicated to the development of superior oral health care products for companion animals, currently developing non-invasive tartar removal products, using an exclusive demonstrated patented technology.

Key Points: 
  • Animal health veterans and human dental experts have combined and formed a start-up company dedicated to the development of superior oral health care products for companion animals, currently developing non-invasive tartar removal products, using an exclusive demonstrated patented technology.
  • The new company, DENTALIS Animal Health, is headquartered in Montreal and is led by:
    President and Product Development Director Kevin McDonnell, serial entrepreneur and co founder of TetraGenx Animal Heath, Provetica AH and Vetio AH.
  • Chief Scientific Officer Hansruedi Siegrist , ex Global Head of Technical Development at Novartis Animal Health and Management Consultant at Elanco AH.
  • We strive to discover new ways to improve and extend our companion animals lives through science based oral health innovation.

Industrial 3D printing success stories from three continents – AMTC 2022 presents an international overview of additive manufacturing development

Retrieved on: 
Thursday, October 6, 2022

Against the backdrop of the current global crises, AMTC 2022, as one of the most important global conferences on additive manufacturing, is all about international cooperation.

Key Points: 
  • Against the backdrop of the current global crises, AMTC 2022, as one of the most important global conferences on additive manufacturing, is all about international cooperation.
  • The most important question is: what can the three major economic regions of America, Europe and Asia learn from each other?
  • In addition to the focus on sustainability, this is one of the primary reasons why the demand for additive manufacturing is increasing.
  • The conference will be topped off by an in-depth look at actual uses of additive manufacturing: Ten blueprint cases demonstrating successful industrial use of additive manufacturing on three continents.

TargImmune Announces Successful Completion of GLP/Tox Studies and Further Reinforcement of Leadership Team with Hire of Head of Technical Development

Retrieved on: 
Tuesday, June 7, 2022

Dr Thommen adds to an impressive senior management team at TargImmune, bringing more than 20 years of experience in biopharmaceutical drug development and scaling biotech manufacturing to clinical supply and commercial launch.

Key Points: 
  • Dr Thommen adds to an impressive senior management team at TargImmune, bringing more than 20 years of experience in biopharmaceutical drug development and scaling biotech manufacturing to clinical supply and commercial launch.
  • Marc's strong history of building CMC organisations at this point in their development will give us the expertise we need to continue to progress the development of our Ta:RNA platform towards patients."
  • I look forward to playing my part in the production of what promises to be an exciting new approach to cancer therapy."
  • TargImmune is dedicated to significantly improving the survival of cancer patients by developing novel targeted anti-cancer therapies which provide a multi-pronged attack against solid tumours.

TargImmune Announces Successful Completion of GLP/Tox Studies and Further Reinforcement of Leadership Team with Hire of Head of Technical Development

Retrieved on: 
Tuesday, June 7, 2022

Dr Thommen adds to an impressive senior management team at TargImmune, bringing more than 20 years of experience in biopharmaceutical drug development and scaling biotech manufacturing to clinical supply and commercial launch.

Key Points: 
  • Dr Thommen adds to an impressive senior management team at TargImmune, bringing more than 20 years of experience in biopharmaceutical drug development and scaling biotech manufacturing to clinical supply and commercial launch.
  • Marc's strong history of building CMC organisations at this point in their development will give us the expertise we need to continue to progress the development of our Ta:RNA platform towards patients."
  • I look forward to playing my part in the production of what promises to be an exciting new approach to cancer therapy."
  • TargImmune is dedicated to significantly improving the survival of cancer patients by developing novel targeted anti-cancer therapies which provide a multi-pronged attack against solid tumours.

MAG Silver Reports First Quarter Financial Results

Retrieved on: 
Tuesday, May 17, 2022

The average silver head grade for the mineralized development and initial stope material processed in Q1 2022 was 597 g/t (Q1 2021 458 g/t).

Key Points: 
  • The average silver head grade for the mineralized development and initial stope material processed in Q1 2022 was 597 g/t (Q1 2021 458 g/t).
  • During the quarter ended March 31, 2022, 54% of the total tonnage processed was through the Saucito plant.
  • The Juanicipio project team delivered the 4,000 tpd processing plant for commissioning in the fourth quarter of 2021.
  • Dr. Megaw is not independent as he is an officer and a paid consultant of MAG Silver.

SU IMC will attend JEC World in Paris for new collaborations

Retrieved on: 
Thursday, April 28, 2022

Sabanc University Integrated Manufacturing Technologies Research and Application Center (SU IMC) will attend JEC World 2022, the largest international gathering of the composites industry, which will take place on May 3-5 in Paris.

Key Points: 
  • Sabanc University Integrated Manufacturing Technologies Research and Application Center (SU IMC) will attend JEC World 2022, the largest international gathering of the composites industry, which will take place on May 3-5 in Paris.
  • Sabanc University Integrated Manufacturing Technologies Research and Application Center (SU IMC), a leading industrial-scale research and technology development center in Istanbul / Turkey, is attending the leading international composites show, JEC World, for new collaborations.
  • SU IMC supports all industries in relation to composite materials, composite part production and additive manufacturing technologies.
  • SU IMC provides an environment of basic and applied research, product development, graduate programs, and lifelong learning programs.

Progenity Appoints Paul Shabram to Lead Technical Operations of the Company’s Ingestible Drug/Device Platforms

Retrieved on: 
Monday, April 25, 2022

We are delighted to have Paul Shabram on board as we accelerate and expand our development programs, said Adi Mohanty, Chief Executive Officer.

Key Points: 
  • We are delighted to have Paul Shabram on board as we accelerate and expand our development programs, said Adi Mohanty, Chief Executive Officer.
  • Before joining Progenity, Mr. Shabram formed Ventana BioSciences Consulting to support developers of vaccines and cancer therapeutics.
  • Progenity also announced the grant of an inducement award to Paul Shabram pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • Progenity claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

Invert Adds Further Carbon Credit Experience and Leadership to Team

Retrieved on: 
Thursday, March 3, 2022

Invert Inc. (Invert), a specialized carbon emissions reduction and offsetting company, is pleased to announce that it has expanded its team to add new carbon project expertise and IT development leadership.

Key Points: 
  • Invert Inc. (Invert), a specialized carbon emissions reduction and offsetting company, is pleased to announce that it has expanded its team to add new carbon project expertise and IT development leadership.
  • Matt is a forester specializing in carbon projects and has over 20 years of experience in forest carbon methodology development, forest inventory techniques, and carbon markets.
  • Matt is co-author of an IFM carbon methodology under the American Carbon Registry and is currently part of a team writing a biochar carbon methodology for Verra, one of the leading carbon credit standard agencies.
  • With their addition to Invert, we have further strengthened the carbon credit team with decades of experience across forestry, blue carbon, regenerative agriculture and technology-related projects.

Sigilon Therapeutics Appoints Sarah Yuan, Ph.D., as Chief Technical Operations Officer

Retrieved on: 
Tuesday, February 22, 2022

CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform, today announced the appointment of Sarah Yuan, Ph.D., as Chief Technical Operations Officer, effective March 7th, 2022.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform, today announced the appointment of Sarah Yuan, Ph.D., as Chief Technical Operations Officer, effective March 7th, 2022.
  • We are delighted to welcome Sarah, a biopharma veteran, to the Sigilon team, said Rogerio Vivaldi, M.D., President and CEO of Sigilon.
  • Prior to joining Sigilon Therapeutics, Dr. Yuan served as Vice President of Process and Analytical Development at 2seventy bio, the oncology spinoff of bluebird bio.
  • Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform.